Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
June 22 2020 - 9:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION
OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS
13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-35619
Stemline Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
(646) 502-2311
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.01 per share
(Title of each class of securities covered
by this Form)
None
(Titles of all other classes of securities
for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate
the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
Rule 12g-4(a)(1)
|
x
|
|
|
|
|
|
|
Rule 12g-4(a)(2)
|
o
|
|
|
|
|
|
|
Rule 12h-3(b)(1)(i)
|
x
|
|
|
|
|
|
|
Rule 12h-3(b)(1)(ii)
|
o
|
|
|
|
|
|
|
Rule 15d-6
|
o
|
|
|
|
|
|
|
Rule 15d-22(b)
|
o
|
|
|
|
|
Approximate number of holders of record
as of the certification or notice date: 1
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, Stemline Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by
the undersigned duly authorized person.
|
Date:
|
June 22, 2020
|
|
By:
|
/s/ David G. Gionco
|
|
|
|
|
|
|
Name:
|
David G. Gionco
|
|
|
|
|
|
|
Title:
|
Senior Vice President of Finance and
Chief Accounting Officer
|
|
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024
